TriSalus Life Sciences, Inc. - Common Stock (TLSI)

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief Executive Officer M

TriSalus (TLSI) Q4 2025 Earnings Call Transcript

TriSalus Q3 2025 results show strong 57% revenue growth but a wider-than-expected EPS loss. The company reaffirmed its 50% full-year growth outlook.

TriSalus (TLSI) Q3 2025 Earnings Call Transcript

TriSalus Life Sciences reports strong Q2 2025 revenue growth of 52% YoY to $11.2M, beating estimates. Losses narrow as commercialization of TriNav and PEDD platform gains momentum.

The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024.

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.

TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.